Oral PCSK9 inhibitor, AZD0780, demonstrated a significant 50.7% reduction in LDL cholesterol levels in the Phase IIb PURSUIT ...

Winrevair (sotatercept-csrk), compared to placebo, reduced the risk of all-cause death, lung transplantation, and hospitalization.

In this video interview, Craig Lipset, co-chair, Decentralized Trials & Research Alliance (DTRA), highlights how recent funding cuts are impacting critical research resources.

Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and ...

Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...

In this video interview, Craig Lipset, co-chair, Decentralized Trials & Research Alliance (DTRA), discusses how the current political climate is affecting diversity in clinical research and how ...

Compared to osimertinib, Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) significantly extended overall survival.

Based on additional results from the Phase III PSMAfore clinical trial, the therapy is now approved for use prior to ...

In this video interview, Rachael Higgins, chief commercial officer, PicnicHealth, discusses findings from the report and the ...

Andrew Mackinnon, Executive GM, Medable, discusses how AI-driven innovations are streamlining clinical trials through ...

Leveraging artificial intelligence-powered stochastic methods for clinical data review represents a significant leap beyond ...

In this video interview, Rachael Higgins, chief commercial officer, PicnicHealth, highlights how addressing these challenges ...